Apnimed to Present Five Abstracts, Including Two Late-Breakers at CHEST 2026GlobeNewsWire · Oct 12, 2026
Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Oct 2, 2026
Apnimed, Inc. (NASDAQ:APMD) Stock Short Interest Jumps 55.7%Defense World · Oct 1, 2026
Apnimed, Inc. (NASDAQ:APMD) Given Consensus Rating of “Moderate Buy” by BrokeragesDefense World · Sep 22, 2026
Apnimed: What We Know Heading Into The Feb PDUFASeeking Alpha · Sep 10, 2026
Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire · Sep 8, 2026Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.